Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Down – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $15.21, but opened at $14.21. Tonix Pharmaceuticals shares last traded at $16.27, with a volume of 515,692 shares changing hands.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Sunday, February 2nd. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Down 11.1 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a market capitalization of $2.49 billion, a P/E ratio of -0.25 and a beta of 2.07. The stock has a fifty day moving average price of $0.82 and a 200 day moving average price of $0.45.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($23.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($203.00) by $180.00. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. On average, research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.